105P Interim data on first-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) from the German non-interventional study (NIS) FINN

Key Points

The study aims to evaluate the incidence of adverse events in patients with metastatic non-small cell lung cancer receiving different treatment sequences.
Identified adult patients from hospital records, outpatient care, and pharmacy claims.
Classified patients into TKI cohort and ICI-TKI cohort based on treatment order.
Descriptively assessed the incidence of adverse events without causal comparisons.
Severe pneumonitis occurred more frequently in the ICI-TKI cohort (6.1% vs 3.7%).
Chronic pneumonitis rates were similar in both cohorts (2.5% vs 2.4%).
Severe gastrointestinal adverse events occurred in 1.9% of the ICI-TKI cohort and 2.0% of the TKI cohort.
Chronic psychiatric adverse events were more common in the ICI-TKI cohort (3.5% vs 2.4%).

Cohort study reports adverse events among patients with metastatic non-small cell lung cancer, indicating significant findings on treatment toxicity.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Schumann et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share